REGENERON PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.3 | $14.2 | $13.1 | $12.2 | $16.1 |
| Operating income | $3.6 | $4.0 | $4.0 | $4.7 | $8.9 |
| Net income | $4.5 | $4.4 | $4.0 | $4.3 | $8.1 |
| Cash Flow Statement | |||||
| Free cash flow | $4.1 | $3.7 | $3.9 | $4.4 | $6.5 |
| Dividends | $0.4 | $0.0 | $0.0 | — | — |
| Share repurchases | $3.4 | $2.6 | $2.2 | $2.1 | $1.6 |
Shares outstanding 103.0M · Free float 92.6%
Annual filing data through FY ended December 31, 2025; float as of October 8, 2026.